Literature DB >> 8473426

A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization.

M J MacDougall1, S L Tan, A Balen, H S Jacobs.   

Abstract

The outcome of in-vitro fertilization and embryo transfer (IVF-ET) was compared in 76 patients with polycystic ovaries (PCO) diagnosed on pre-treatment ultrasound scan, and 76 control patients who had normal ovaries and were matched for age, cause of infertility and stimulation regimen. Despite receiving significantly less human menopausal gonadotrophin (HMG), patients with PCO, as compared with controls, had significantly higher serum oestradiol levels on the day of human chorionic gonadotrophin administration (5940 +/- 255 versus 4370 +/- 240 pmol/l, P < 0.001), developed more follicles (14.9 +/- 0.7 versus 9.8 +/- 0.6, P < 0.001) and produced more oocytes (9.3 +/- 0.6 versus 6.8 +/- 0.5, P = 0.003). However, fertilization rates were reduced in the PCO patients (52.8 +/- 3.4% versus 66.1 +/- 3.4%, P = 0.007). There was no significant difference in cleavage rates. The pregnancy rate/embryo transfer was 25.4% in the PCO group and 23.0% in the group with normal ovaries. There were three high order multiple pregnancies in the PCO group compared with none in the group with normal ovaries. Of the PCO patients, 10.5% developed moderate/severe ovarian hyperstimulation syndrome (OHSS) compared with none of the controls (P = 0.006). Patients with and without PCO undergoing IVF have comparable pregnancy and livebirth rates. However, it is important to diagnose PCO before ovarian stimulation is initiated as these patients are more likely to develop moderate or severe OHSS following IVF-ET.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473426     DOI: 10.1093/oxfordjournals.humrep.a138029

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  25 in total

1.  Retrieval, maturation, and fertilization of immature oocytes obtained from unstimulated patients with polycystic ovary syndrome.

Authors:  N G Beckers; M H Pieters; L Ramos; G H Zeilmaker; B C Fauser; D D Braat
Journal:  J Assist Reprod Genet       Date:  1999-02       Impact factor: 3.412

2.  Number and size of antral follicles as predictive factors in vitro fertilization and embryo transfer.

Authors:  M Pöhl; M Hohlagschwandtner; A Obruca; G Poschalko; M Weigert; W Feichtinger
Journal:  J Assist Reprod Genet       Date:  2000-07       Impact factor: 3.412

Review 3.  The treatment of patients with polycystic ovaries undergoing IVF.

Authors:  S Franks
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

Review 4.  In vitro fertilization treatment in patients with polycystic ovaries.

Authors:  A Shulman; J Dor
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

Review 5.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

6.  Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome.

Authors:  A O Awonuga; N Dean; J Zaidi; R U Pittrof; J S Bekir; S L Tan
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

7.  IVM is an alternative for patients with PCO after failed conventional IVF attempt.

Authors:  Bulent Gulekli; Muge Kovali; Fulya Aydiner; Sule Dogan; Seda S Dogan
Journal:  J Assist Reprod Genet       Date:  2011-06-07       Impact factor: 3.412

8.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

9.  In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.

Authors:  Geoffrey H Trew; Adam P Brown; Samantha Gillard; Stuart Blackmore; Christine Clewlow; Paul O'Donohoe; Radoslaw Wasiak
Journal:  Reprod Biol Endocrinol       Date:  2010-11-08       Impact factor: 5.211

10.  Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function.

Authors:  David Barad; Hyama Brill; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2007-12-11       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.